Dr. Picozzi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1100 9th Ave
Virginia Mason Med Ctr, Div Hem/Onc
Seattle, WA 98101Phone+1 206-223-6600- Is this information wrong?
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1981 - 1982
- Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
- Stanford University School of MedicineClass of 1978
Certifications & Licensure
- CA State Medical License 1981 - Present
- WA State Medical License 1985 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer Start of enrollment: 2003 Mar 01
- Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT Start of enrollment: 2008 Sep 01
- A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.Lyanne A Delgado-Coka, Lucia Roa-Peña, Sruthi Babu, Michael Horowitz, Emanuel F Petricoin 3rd, Lynn M Matrisian, Edik M Blais, Natalia Marchenko, Felicia D Allard, Ali...> ;American Journal of Clinical Pathology. 2024 Apr 20
- Pancreatic cancer: new approaches to drug therapy.Vincent J Picozzi> ;International Journal of Surgery. 2024 Apr 4
- Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and...Schroeder, B., Mandelson, M., Picozzi, V.> ;Cancers. 2023 Nov 26
- Join now to see all
Journal Articles
- Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor InitiativeSameh Mikhail, Vincent J Picozzi, Clinical Cancer Research
Lectures
- Prognostic value (PV) of pathologic response (PR) to neoadjuvant chemotherapy (NC) alone in resected pancreatic cancer (PDAC): Initial analysis.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 cl...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
- Virginia Mason Helps Lead National Clinical Trial to Accelerate Exploration, Approval of New Pancreatic Cancer TherapiesMay 7th, 2020
- Pancreatic Cancer Advocates Rally for More Federal Research FundingJune 24th, 2019
- Tyme Schedules Conference Call to Discuss SM-88 Preliminary Phase II Pancreatic Cancer Data on Friday, January 18thJanuary 15th, 2019
- Join now to see all
Hospital Affiliations
- Virginia Mason Medical CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: